MO8833A_supplementary_materials_v2_Figures.pdf (646.42 kB)
Supplementary Figures – Indirect comparison of pembrolizumab monotherapy versus nivolumab+ipilimumab in first-line metastatic lung cancer
figure
posted on 2022-01-25, 09:05 authored by Figshare Future Science GroupFigshare Future Science Group, Balazs Halmos, Thomas Burke, Chrysostomos Kalyvas, Ralph Insinga, Kristel Vandormael, Andrew Frederickson, Bilal Piperdi
Figure S1 Kaplan–Meier curves before matching adjustment for a) overall survival b) progression-free survival
Figure S2 Forest plot of pembrolizumab versus nivolumab+ipilimumab for overall survival and progression-free survival in patients with PD-L1 TPS 1–49% and ≥50%a |